Most pharmacovigilance software comparisons are written for a pharma company evaluating a system for its own products. A CRO is solving a different problem. You are not choosing a safety database — you are choosing the operating model you will run many sponsors on simultaneously, each with their own products, their own reporting rules, their own SOPs, their own reference safety information, and a contractual right to know that their data is not visible to anyone else.
That changes which criteria matter. Feature parity across the top platforms is reasonably good; where they differ sharply for a CRO is in tenant architecture, per-sponsor reporting, and the marginal cost and time of onboarding sponsor number twelve.
This guide names no winners
We build PVgenix, so treat our conclusions accordingly. What follows is a vendor-neutral set of criteria and questions you can put to every platform on your shortlist, including ours. We do not publish capability claims about competitor products — those change constantly and only the vendor can confirm them. Verify anything decision-critical directly with each vendor, in writing.
Tenant isolation you can evidence
Not just role-based permissions — a tenant architecture you can demonstrate to a sponsor during due diligence. Ask whether isolation is logical or physical, and what evidence you can hand a sponsor's auditor.
Per-tenant configuration
Each sponsor needs their own reporting rules, workflow states, intake forms, code lists, reference safety information, and review gates — configured without a code change or a vendor ticket.
Onboarding economics
The cost and elapsed time to add sponsor number two, and number twelve. If each new client requires a fresh implementation project, the platform caps your growth rather than supporting it.
Per-sponsor compliance reporting
On-time submission rate is the KPI you report monthly, per sponsor. It should come out of the system scoped to that sponsor, not out of a spreadsheet someone maintains.
Submission breadth
Your sponsors' obligations differ by market and by study. You need E2B(R2) and E2B(R3), CIOMS I, MedWatch 3500A, and a rules engine you can configure per sponsor and per protocol.
Data portability at contract end
Contracts end. You need a clean, documented E2B export for a sponsor's data when it does — as a standard capability, not a professional-services engagement.
Qualification burden per tenant
Understand what has to be re-qualified when you add a tenant versus when the platform changes, and what documentation the vendor supplies to support it.
During sponsor due diligence you will be asked how their data is kept separate from your other clients'. A vague answer costs you contracts. There are two credible models, and you should know which one you are buying and be able to describe it precisely.
| Model | What it means | Suits |
|---|---|---|
| Logical isolation (multi-tenant) | One application and database with tenant-scoped access control and data partitioning; each tenant configured independently | Most CRO operations — fastest to provision, lowest cost per tenant, no per-client infrastructure to manage |
| Physical isolation (single-tenant) | A separate application and database instance per client, deployable in a specific environment or region | Sponsors with strict data-residency or internal-hosting requirements written into the contract |
The practical answer for a CRO is usually to have both available. PVgenix runs multi-tenant SaaS with logical isolation as the default and dedicated single-tenant deployment for clients who require physical isolation, both from the same codebase — so a sponsor with unusual residency requirements does not force you onto a second platform with different behaviour.
This is the criterion most often missed in a CRO evaluation. A platform that takes six weeks and a paid professional-services engagement per new sponsor has quietly set a ceiling on how fast your PV business can grow, regardless of how good the case processing is.
Ask each vendor for the elapsed time and the cost for a second tenant, and who performs the work. For PVgenix the initial platform build takes approximately three days of IT provisioning plus three days for setup documentation handover; after that, each new tenant is self-provisioned from the portal with no involvement from our IT team and about one day of documentation. Those figures cover IT provisioning and documentation only — the sponsor-specific configuration, your qualification activities, and your SOP work sit on top and are led by you.
Separate the vendor's timeline from yours
Every vendor, including us, quotes provisioning time. Your real timeline to processing a sponsor's first case also includes sponsor-specific configuration, qualification execution, SOP updates, UAT, data migration, and training. Ask which of those the vendor performs and which you own, and get it in writing before you plan a sponsor go-live date.
Every sponsor contract carries reporting obligations, and most carry a monthly compliance report. If on-time submission rate is assembled by hand each month, two things follow: it consumes senior time, and it is a manual figure you are contractually asserting. A platform should compute it from the submission records themselves, scoped per sponsor, and surface overdue and at-risk queues to a named owner before a deadline passes rather than after.
See regulatory submission for how PVgenix handles the regulatory clock, the rules engine, acknowledgement reconciliation, and the per-sponsor compliance dashboard.
Send this to every vendor and compare written answers. The questions are deliberately specific — vague answers are themselves a signal.
| Question | What a good answer looks like |
|---|---|
| Is tenant isolation logical or physical, and what evidence can we give a sponsor's auditor? | A clear architectural description plus documentation you are permitted to share during due diligence |
| What is the elapsed time and cost to onboard our second sponsor? Our twelfth? | A specific figure, and confirmation of whether we can self-provision or must raise a vendor request |
| Can each sponsor have different reporting rules, workflows, RSI, and code lists? | Yes, configured per tenant by an administrator without a code change or vendor ticket |
| Does on-time submission rate come out of the system per sponsor? | A live dashboard scoped by tenant, computed from submission records — not an export we aggregate |
| Is the AS2 gateway included or separately licensed? | Included, ideally — a separate gateway adds licence cost and another component to your qualification scope |
| Which E2B versions and form outputs are supported? | E2B(R2) and E2B(R3), CIOMS I, and MedWatch 3500A at minimum, with per-market rule configuration |
| How do we export one sponsor's data when the contract ends? | Standard E2B export plus attachments, documented, without a paid engagement |
| What has to be re-qualified when you release an update? | A clear change-control and release process, with regression evidence and documentation supplied |
| Are MedDRA and WHO-DD licences included? | Almost certainly not — confirm that they are your responsibility and budget for them |
| What is the total first-year cost for our expected sponsor count? | A figure including implementation, qualification support, hosting, migration, training, and support tier |
Factual statements about our platform, for comparison against the answers you collect elsewhere.
| Criterion | PVgenix |
|---|---|
| Tenant model | Multi-tenant SaaS with logical isolation, or dedicated single-tenant with physical isolation — both from one codebase |
| Adding a tenant | Self-provisioned from the portal after the initial platform build, with no IT-team involvement and about one day of documentation |
| Per-tenant configuration | Reporting rules, workflow states, intake form fields and validation, code lists, dictionary versions, RSI, branding, and entitlements |
| Per-sponsor compliance | On-time submission metrics and compliance reporting scoped per sponsor, with overdue and at-risk queues |
| Submission coverage | E2B(R2)/E2B(R3), CIOMS I, MedWatch 3500A, regulatory clock and configurable rules engine, built-in AS2 gateway, ACK reconciliation |
| Case sources | Post-marketing spontaneous and clinical-trial cases, including SUSAR handling and blinding/unblinding workflow |
| Data residency | EU, US, and India region hosting options for GDPR and sponsor-contract requirements |
| Access control | Role-based access control with least-privilege design, e-signature capture, and tamper-evident audit logging |
| Documentation | VMP, URS, FS, DS, IQ/OQ/PQ, RTM, and SOP templates to support your qualification |
| Migration | E2B transfer plus data migration tooling for legacy extraction, field mapping, and reconciliation |
Validation is environment-specific
PVgenix is validation-ready and audit-ready: it ships with a complete IQ/OQ/PQ documentation package to support client-led validation. 'Validated' is a state achieved only after qualification is executed in a specific client environment.
Where responsibility sits
PVgenix develops and delivers the software, the environment setup, and the supporting documentation. The client and their qualified PV personnel own PV decisions, regulatory interpretation, validation execution, and compliance obligations.
- You need one vendor spanning pharmacovigilance, clinical operations, and regulatory affairs, and the single-suite integration is the value you are buying
- Your sponsors contractually mandate a specific named platform — this happens, and it is not negotiable from your side
- You want the vendor to provide pharmacovigilance services or regulatory advice; we deliver software, and PV decisions, regulatory interpretation, and SOP content stay with your qualified personnel
- You need a niche regional submission route outside the coverage described above — ask us, and expect a straight answer either way
The short version
For a CRO, the deciding criteria are tenant isolation you can evidence to a sponsor, per-tenant configuration without vendor tickets, the cost and time of onboarding the next sponsor, and per-sponsor compliance reporting that comes out of the system. Feature checklists will look similar across your shortlist; these four will not.
Next: pharmacovigilance software cost for the economics, ICSR management software for the case record detail, and deployment and onboarding for both deployment models and the provisioning timelines in full.
Frequently asked questions
Common questions
Four criteria matter more for a CRO than for a single-product pharma buyer: tenant isolation you can evidence during sponsor due diligence; per-tenant configuration of reporting rules, workflows, code lists, and reference safety information without a code change; the cost and elapsed time of onboarding each additional sponsor; and per-sponsor compliance reporting such as on-time submission rate computed by the system rather than assembled manually. Core case-processing feature sets tend to look similar across a shortlist; these four differ sharply.
Multi-tenant means one application instance serves multiple client organisations, with each client's data logically isolated and each tenant configured independently — separate reporting rules, workflows, code lists, reference safety information, and access control. For a CRO it is the model that makes onboarding a new sponsor a provisioning task rather than a new deployment. Where a sponsor contract requires physical separation, a dedicated single-tenant deployment provides an isolated application and database instead.
After the one-time initial platform build (approximately three days of IT provisioning plus three days of setup documentation), each new tenant is self-provisioned from the portal with no involvement from our IT team and about one day of documentation. That covers IT provisioning and documentation handover only. Sponsor-specific configuration, your qualification activities, SOP updates, UAT, any data migration, and training sit on top of it and are led by you.
In the multi-tenant SaaS model, data is logically isolated per tenant with role-based, tenant-scoped access control, least-privilege design, encryption in transit and at rest, and tamper-evident audit logging of every access and change. For sponsors whose contracts require physical separation, a dedicated single-tenant deployment provides an isolated application and database, optionally in a specified region.
Yes. Reporting rules, workflow states and review gates, intake form fields and validation rules, code lists, dictionary versions, reference safety information, and entitlements are configured per tenant from the admin console. Study-specific reporting rules can also be configured per protocol for clinical-trial cases.
Case data can be exported in E2B format, which is the vendor-neutral transfer standard, along with source documents and attachments. Treat export rights, formats, timelines, and any associated cost as a contractual point to settle before you sign with any vendor — including the retention period that applies after a contract ends.